|
1
|
Capecitabine as adjuvant treatment for stage III colon cancer.
|
N Engl J Med
|
2005
|
6.22
|
|
2
|
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
|
J Clin Oncol
|
2008
|
5.28
|
|
3
|
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
|
J Clin Oncol
|
2005
|
2.77
|
|
4
|
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
|
J Clin Oncol
|
2003
|
1.97
|
|
5
|
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
|
Clin Cancer Res
|
2008
|
1.94
|
|
6
|
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
|
J Clin Oncol
|
2003
|
1.37
|
|
7
|
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
|
Clin Cancer Res
|
2007
|
1.32
|
|
8
|
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
|
Cancer Chemother Pharmacol
|
2010
|
1.22
|
|
9
|
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
|
Cancer
|
2010
|
1.22
|
|
10
|
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
1.17
|
|
11
|
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
|
J Hematol Oncol
|
2009
|
1.08
|
|
12
|
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
|
Am J Clin Oncol
|
2008
|
1.05
|
|
13
|
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.93
|
|
14
|
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.92
|
|
15
|
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
|
Cancer Res
|
2010
|
0.92
|
|
16
|
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
|
Clin Colorectal Cancer
|
2009
|
0.87
|
|
17
|
A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
|
Breast Cancer Res Treat
|
2010
|
0.83
|
|
18
|
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
|
Cancer
|
2014
|
0.82
|
|
19
|
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
|
Breast Cancer Res Treat
|
2014
|
0.78
|
|
20
|
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2011
|
0.77
|
|
21
|
A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
|
Cancer Invest
|
2011
|
0.76
|